MarketCap
Facebook
X
TelegramDicerna Pharmaceuticals, Inc. Betriebsaufwand 2011-2026 | DRNA
Betriebsaufwand Jährlich Dicerna Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 278 M | 152 M | 67.4 M | 62.9 M | 60 M | 63.2 M | 45.1 M | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 278 M | 45.1 M | 104 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 21.87 | 2.15 % | $ 1.02 B |  USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
20.7 M | $ 0.94 | 5.23 % | $ 6.91 M | China |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
ACADIA Pharmaceuticals
ACAD
|
708 M | $ 22.67 | 3.23 % | $ 3.76 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Esperion Therapeutics
ESPR
|
343 M | $ 2.02 | 5.5 % | $ 420 M | USA |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
Galectin Therapeutics
GALT
|
20.1 M | $ 2.45 | 5.15 % | $ 157 M | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | USA |
 |
Heron Therapeutics
HRTX
|
281 M | $ 1.2 | 0.42 % | $ 200 M | USA |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
ImmuCell Corporation
ICCC
|
9.8 M | $ 8.24 | -1.38 % | $ 74.4 M | USA |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M |  Canada |
 |
InflaRx N.V.
IFRX
|
52.4 M | $ 1.52 | 2.36 % | $ 152 M | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
23.4 K | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 103.09 | -2.25 % | $ 27.2 B | Germany |
 |
Avenue Therapeutics
ATXI
|
4.49 M | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
Innate Pharma S.A.
IPHA
|
63 M | $ 1.36 | -1.45 % | $ 235 M | France |
 |
Aquestive Therapeutics
AQST
|
85.5 M | $ 4.17 | 2.21 % | $ 446 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
137 M | $ 23.73 | 2.02 % | $ 3.02 B | USA |
 |
Inventiva S.A.
IVA
|
36.2 M | $ 5.18 | 0.49 % | $ 138 M | France |
 |
Jaguar Health
JAGX
|
36 M | $ 0.35 | -9.42 % | $ 816 K | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M |  Israel |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.45 | 0.35 % | $ 386 M | Britain |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
KalVista Pharmaceuticals
KALV
|
161 M | $ 20.06 | 2.18 % | $ 1.08 B | Britain |
 |
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 3.03 | 4.12 % | $ 4.99 M | Israel |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
115 M | $ 233.96 | 1.16 % | $ 4.28 B | USA |